Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers
Open Access
- 1 January 2008
- journal article
- Published by Springer Nature in International Archives of Medicine
- Vol. 1 (1) , 24
Abstract
Cystic fibrosis is the most common and best known genetic disease involving a defect in transepithelial Cl- transport by mutations in the CF gene on chromosome 7, which codes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). The most serious symptoms are observed in the lungs, augmenting the risk of bacterial infection. The objective of this review was to describe the bacterial pathogens colonizing patients with cystic fibrosis. A systematic search was conducted using the international bibliographic databanks SCIELO, HIGHWIRE, PUBMED, SCIRUS and LILACS to provide a useful and practical review for healthcare workers to make them aware of these microorganisms. Today, B. cepacia, P. aeruginosa and S. aureus are the most important infectious agents in cystic fibrosis patients. However, healthcare professionals must pay attention to emerging infectious agents in these patients, because they represent a potentially serious future problem. Therefore, these pathogens should be pointed out as a risk to these patients, and hospitals all over the world must be prepared to detect and combat these bacteria.Keywords
This publication has 81 references indexed in Scilit:
- Impact of Pseudomonas and Staphylococcus Infection on Inflammation and Clinical Status in Young Children with Cystic FibrosisThe Journal of Pediatrics, 2009
- Molecular Epidemiology ofMycobacterium abscessus, with Focus on Cystic FibrosisJournal of Clinical Microbiology, 2007
- Global Distribution of Panton-Valentine Leukocidin–positive Methicillin-resistantStaphylococcus aureus,2006Emerging Infectious Diseases, 2007
- Antimicrobial Peptide Therapeutics for Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2005
- Sputumversusbronchoscopy for diagnosis ofPseudomonas aeruginosabiofilms in cystic fibrosisEuropean Respiratory Journal, 2004
- Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agentsThorax, 2003
- Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in ratsJournal of Antimicrobial Chemotherapy, 2003
- Characteristics ofStaphylococcus aureus, isolated from airways of cystic fibrosis patients, and their small colony variantsFEMS Immunology & Medical Microbiology, 2002
- Molecular Epidemiology of Community‐AcquiredStaphylococcus aureusin Families with and without Cystic Fibrosis PatientsThe Journal of Infectious Diseases, 2000
- Antibiotic Susceptibility of Multiply Resistant Pseudomonas aeruginosa Isolatedfrom Patients with Cystic Fibrosis, Including Candidates for TransplantationClinical Infectious Diseases, 1996